InvestSMART

Nova Eye Medical Limited (ASX: EYE) - Announcements

Current share price for EYE : $0.145 0.01 (6.45%)+

ASX company news and announcements for Nova Eye Medical Limited (EYE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nova Eye Medical Limited (EYE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nova Eye Medical Limited (EYE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nova Eye Medical Limited (EYE)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$41 Notification of cessation of securities - EYE 5 Aug 2026 12:41PM $0.140 $0.145 risen by 3.57%
$41 Investor Webinar Tuesday 4 August 2026 @ 11.30 AEST 29 Jul 2026 11:10AM $0.125 $0.145 risen by 16%
$41 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jul 2026 11:03AM $0.120 $0.145 risen by 20.83%
$41 Application for quotation of securities - EYE 10 Jul 2026 2:39PM $0.115 $0.145 risen by 26.09%
$41 Notification of cessation of securities - EYE 25 Jun 2026 2:55PM $0.105 $0.145 risen by 38.10%
$41 Notification of cessation of securities - EYE 25 Jun 2026 2:49PM $0.105 $0.145 risen by 38.10%
$41 Notification regarding unquoted securities - EYE 6 May 2026 3:04PM $0.125 $0.145 risen by 16%
$41 Application for quotation of securities - EYE 6 May 2026 3:02PM $0.125 $0.145 risen by 16%
$41 EYE lifts Sales Guidance 5 May 2026 9:48AM $0.125 $0.145 risen by 16%
$41 Q3FY26 Investor Presentation May26 5 May 2026 9:47AM $0.125 $0.145 risen by 16%
$41 Investor Webinar Tuesday 5 May @ 11.30 AEST 30 Apr 2026 10:27AM $0.130 $0.145 risen by 11.54%
$41 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 8:26AM $0.145 $0.145 fallen by 0%
$41 Application for quotation of securities - EYE 11 Mar 2026 9:31AM $0.148 $0.145 fallen by 1.69%
$41 EYE Receives EU MDR Certification 3 Mar 2026 9:14AM $0.145 $0.145 fallen by 0%
$41 Investor Webinar Tuesday 3 March @11.30 AEDT 26 Feb 2026 8:23AM $0.160 $0.145 fallen by 9.38%
$41 Investor Presentation Half Year Results 26 Feb 2026 8:16AM $0.160 $0.145 fallen by 9.38%
$41 EYE Delivers Sales Growth and Improves Bottom Line 26 Feb 2026 8:16AM $0.160 $0.145 fallen by 9.38%
$41 Half Yearly Report and Accounts 26 Feb 2026 8:15AM $0.160 $0.145 fallen by 9.38%
$41 Re-lodgement of Appendix 4G 11 Feb 2026 1:46PM $0.170 $0.145 fallen by 14.71%
$41 Peer-Reviewed Real-World Evidence Supports iTrack 4 Feb 2026 11:30AM $0.175 $0.145 fallen by 17.14%
$41 Investor Webinar Monday 2 February @ 11.30 AEDT 29 Jan 2026 3:23PM $0.175 $0.145 fallen by 17.14%
$41 Quarterly Activities/Appendix 4C Cash Flow Report 29 Jan 2026 8:44AM $0.195 $0.145 fallen by 25.64%
$41 ITrack Registry Clinical Data Update 27 Jan 2026 9:45AM $0.190 $0.145 fallen by 23.68%
$41 Investor Webinar Presentation December 2025 19 Jan 2026 10:24AM $0.160 $0.145 fallen by 9.38%
$41 Investor Webinar 19 January 2026 15 Jan 2026 9:09AM $0.160 $0.145 fallen by 9.38%

1 - 25 of 352 results

Page 1 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.